drugset / Trial / NCT05324293
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
NaSingle-groupOpen-labelTreatment
Summary
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2023-09-11
- Completion
- 2023-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMI-115 | Monoclonal antibody | 240 mg | Subcutaneous |